Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Plus TherapeuticsPSTV +6.03%28 EV-to-OCF is -0.59 as of Jul. 31, 2026. GuruFocus rates PSTV with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, Plus Therapeutics ranks worse than 66.67% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Plus Therapeutics's Enterprise Value is $12.25 Mil.
Plus Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-20.84 Mil. Therefore, Plus Therapeutics's EV-to-OCF for today is -0.59.
The historical rank and industry rank for Plus Therapeutics's EV-to-OCF or its related term are showing as below:
PSTV'
s EV-to-OCF Range Over the Past 10 Years
Min: -2.71 Med: 0.36 Max: 0.73
Current: -0.59
During the past 13 years, the highest EV-to-OCF of Plus Therapeutics was 0.73. The lowest was -2.71. And the median was 0.36.
PSTV's EV-to-OCF is ranked worse than 66.67% of 1410
companies
in the Biotechnology industry
Industry Median: -3.345
vs PSTV: -0.59
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Plus Therapeutics (NAS:PSTV) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Plus Therapeutics's PE Ratio (TTM) for today is calculated as:
Plus Therapeutics's share price for today is $3.87.
Plus Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.330.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Plus Therapeutics EV-to-OCF Related Terms
Plus Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Plus Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Plus Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Plus Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Plus Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Plus Therapeutics's EV-to-OCF falls into.
Plus Therapeutics's current Enterprise Value is $12.25 Mil.
Plus Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics (PSTV) has a EV-to-OCF of -0.59 as of Jul. 31, 2026. According to the industry distribution chart, Plus Therapeutics ranks #940 out of 1410 companies in the Biotechnology industry, placing it in the top 66.7%.
Is Plus Therapeutics' EV-to-OCF too high?
Plus Therapeutics' current EV-to-OCF is -0.59. Based on the distribution chart, Plus Therapeutics ranks #940 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Plus Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' EV-to-OCF compare to PVCT and ATNM?
According to the Biotechnology industry distribution chart, Plus Therapeutics ranks #940 out of 1410 companies for EV-to-OCF. This places Plus Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Plus Therapeutics's current EV-to-OCF is -0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (PSTV) has a current EV-to-OCF of -0.59. The current EV-to-OCF is -0.59. Plus Therapeutics' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Plus Therapeutics (PSTV), the current EV-to-OCF is -0.59 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
28GF Score
Get the complete analysis for PSTV
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PSTV has been successfully added to your 
